EA042014B1 - STRESS TRACKING INHALATOR - Google Patents

Description

The field of technology to which the invention belongs

The present invention relates to an aerosol generating inhaler having a sensor for monitoring the user's stress level during use.

Background of the invention

Inhalers such as electronic cigarettes or vaping devices are becoming more and more popular. They are used to deliver a flavor or stimulant to a user in the form of an aerosol without combustion. Users of such inhalers may wish to control the amount of flavor or stimulant released based on their preference or other factors.

Vaping devices available on the market are often standardized and may not meet the needs of individuals.

Therefore, there is a need for a device that can adapt to its user and manage the delivery of an aerosol in a safe and reliable manner.

The essence of the invention

According to an aspect of the present invention, an aerosol generating inhaler is provided, comprising: a housing having an air flow path defined between an air inlet and an air outlet of the housing, the air outlet allowing the generated aerosol to exit; a galvanometer located on the main part of the inhaler, the galvanometer is configured to measure the galvanic skin reflex to determine the stress level of the user of the inhaler; and a control device configured to control the release of the aerosol based on the determined stress level.

Advantageously, the inhaler according to the present invention can determine the user's vaping stress level and, based on this, control the amount of aerosol delivered to the user for inhalation. Because the galvanometer is built into the inhaler itself, the user does not need to make any extra effort or connect any additional device to the inhaler. Moreover, since the substance contained in the aerosol is adjusted according to the user's current stress level, the user's stress can be maintained at a base level or an optimal level while vaping.

Preferably, the galvanometer is incorporated into the activation switch of the inhaler such that the user's skin comes into contact with the galvanometer when the user interacts with the activation switch to activate the inhaler.

Advantageously, the user does not need to perform any additional step to determine the level of stress, since the galvanometer is activated when the user turns on the inhaler using the activation button.

Preferably, the galvanometer is positioned on the side of the inhaler such that the user's skin comes into contact with the galvanometer when the user holds the inhaler during use.

Advantageously, monitoring of the stress level can be performed continuously during the use of the inhaler by the user.

Preferably, the inhaler further comprises an acceleration sensor for detecting the movements of the user during use of the inhaler.

It is advantageously possible to detect if the user is performing any physical actions that may affect the stress level readings.

Preferably, the control device is configured to ignore the galvanic skin reflex measured by the galvanometer based on movements detected by the acceleration sensor.

Advantageously, the stress level can be determined more accurately by ignoring the stress reading taken at a time when it could be erroneous, such as when the user is performing physical activities while still using the inhaler as determined by the acceleration sensor.

Preferably, the control device is configured to determine the baseline galvanic skin reflex of the user using measurements taken by the galvanometer at different time periods.

It is advantageously possible to determine the user's optimal or normal stress level while vaping by recording the stress level data over time.

Preferably, the base level galvanic skin reflex provides a range with an upper base level limit and a lower base level limit. The baseline galvanic skin reflex may also include a safety threshold, and the control device may be configured to take action when the safety threshold is exceeded.

Advantageously, having a base level range with upper and lower thresholds provides more flexibility and allows for more realistic performance.

- 1 042014 regulation of the inhaler in the interests of the user.

Preferably, the control device is configured to increase or decrease the amount of substance in the released aerosol when the measured galvanic skin reflex is respectively lower or higher than the baseline galvanic skin reflex. The controller may also be configured to increase or decrease the amount of substance in the released aerosol based on the time of day or data associated with the user's vaping activities, including vaping puff duration or vaping puff frequency.

Advantageously, the user's stress level can be adjusted to an optimal level by controlling the amount of aerosol based on the measured stress level.

Preferably, the control device is configured to determine the number of puffs inhaled by the user per unit of time.

Advantageously, it is also possible to determine the user's stress level based on the frequency of puffs inhaled during vaping or the duration of the puffs.

According to another aspect of the present invention, a method of operating an aerosol generating inhaler is provided, comprising: activating the inhaler to release the aerosol from the inhaler; measurement of the galvanic skin reflex with determination of the stress level of the user using a galvanometer located on the main part of the inhaler; and controlling the release of the aerosol based on the determined level of stress.

Brief description of graphic materials

In FIG. 1A shows a stress sensor inhaler according to one aspect of the present invention;

in fig. 1B shows a stress sensor inhaler according to another aspect of the present invention;

in fig. 2 is a block diagram of the various components of the inhaler shown in FIG. 1A and 1B;

in fig. 3A, 3B are block diagrams of the operation of the inhaler shown in FIG. 1A and 1B;

in fig. 4 is a graph showing a picture of a user's stress level during a typical week;

in fig. 5 is a graph showing a comparison of the measured galvanic skin reflex of a user at different time periods with baseline limits.

Detailed description

Various aspects of the present invention will be described below. It should be noted that in the following descriptions of the drawings, the same or like parts are identified by the same or like reference numerals. It should be noted that the graphic materials are schematic and the ratio between the sizes differs from the real one. Therefore, about specific dimensions, etc. should be judged on the basis of the following descriptions. Needless to say, parts are provided, the relative position and the ratio of the mutual sizes of which differs on the joint graphic materials.

In FIG. 1A shows a non-combustible type flavor inhaler 100, which is a device for inhaling flavor without combustion. The inhaler 100 is rod-shaped with the main body 101 extending from the end 102 without a mouthpiece to the end 103 with a mouthpiece. An air channel or path is formed in the body 100 between opposite ends 102, 103.

The inhaler 100 in the present example is an electronic cigarette or vaping device. The inhaler 100 operates by vaporizing or heating an aerosol source contained within the inhaler 100 to release a flavor or stimulant for inhalation by the user through the mouthpiece end 103. The design and operation of such an inhaler is well known in the art and will be understood by a person skilled in the art.

The inhaler 100 also includes an activation switch 104 that can be configured to perform at least one of turning the power supply of the inhaler 100 on and off. inhaler 101.

Today, for various reasons, people like to track their activity level, body characteristics, sleep quality, etc. There are some devices or gadgets available on the market that can do this. However, such devices are either wearable devices, which may be too intrusive for some users, or other non-wearable devices, which may be inconvenient to use or carry around.

Tracking stress levels can be of particular interest because stress affects various other bodily functions. For example, when a subject experiences a high level of stress, his or her heart rate, blood pressure, brain activity are likely to increase, which may have a negative health impact. However, some higher

- 2 042014 Stress levels may be preferable in certain situations, such as during an exam, a difficult task, or an emergency. There are several types of activity that can increase stress levels, such as vigorous physical activity, substance use, or emotional decline. Keeping stress levels under control and managing external stimuli accordingly can help maintain good overall health. It may also be desirable for users of electronic cigarettes or similar devices to control aerosol intake based on their current stress level.

According to one aspect of the present invention, a stress sensor 204 is incorporated into switch 104 such that when a user touches or depresses switch 104 to turn on inhaler 100, sensor 204 measures the user's stress level through skin contact, as detailed below.

In FIG. 1B shows an inhaler 200 similar to the inhaler 100 shown in FIG. 1A, with only one difference. That is, in the inhaler 200, the stress sensor 204 is located not on the activation switch 104, but on the side surface 105 of the body. The sensor 204 may be provided in the form of a strip or a label and placed in such a position that when the user holds the inhaler 200 during use, his or her skin comes into contact with the sensor 204, allowing it to sense the user's stress level.

It should be understood that the inhaler 100, 200 may be of any suitable shape and size and may have various mechanisms of operation. Also, the activation switch 104 may be located on either side or bottom of the inhaler. Preferably, sensor 204 is positioned such that it comes into contact with the user's skin during normal use, without the user having to specifically locate and make contact with the sensor.

In FIG. 2 shows the various components of the inhaler 100, 200. The inhaler 100, 200 includes an aerosol source 201 and a vaporizer 202 that vaporizes the aerosol source 201 to release an aerosol containing flavor and/or stimulant for inhalation by the user. In the present example, the aerosol source 201 is a substance containing nicotine. The aerosol source 201 may be in the form of a solid or a liquid, and it is heated by an evaporator (containing a heat source) to release the aerosol without combustion. The evaporator may comprise a heating coil for evaporating a liquid, or a heating chamber for heating a solid aerosol source (eg, tobacco stick) without combustion, or any other suitable configuration applicable to an aerosol generating device. The evaporator 202 may be powered by a power source 203 . The power supply 203 is, for example, a lithium ion battery. The power supply 203 supplies the power needed to operate the inhaler 100, 200. For example, the power supply 203 supplies power to all other components or modules contained in the inhaler 100, 200.

The aerosol source 201 may include an additional flavor source (not shown) provided on the mouthpiece end 103 side outside of the holder holding the aerosol source 201 and generating a flavor to be inhaled by the user along with the aerosol generated from the aerosol source 201. Examples of a flavoring source that can be used include shredded tobacco, a molded article including raw tobacco shaped into pellets, a molded article including raw tobacco shaped to be in the form of a sheet. The flavor source may include a plant such as mint or herbs. A flavoring agent, such as menthol, may be added to the flavoring source.

The inhaler 100, 200 further comprises a stress sensor. Preferably, the stress sensor is a galvanometer 204 that measures the skin electrical activity of the user. In particular, the galvanometer 204 determines the user's stress level by measuring the galvanic skin reflex (GSR), or skin electrical conductivity resulting from changes in sweat gland activity that reflects the user's emotional state. Because skin electrical conductivity is typically obtained in the areas of the arms and legs, the electrodes present in the galvanometer 204 are in contact with the user's hand when the user is using the inhaler.

The inhaler 100, 200 also includes a control device 206 that is configured to control various modules or components in the inhaler. The controller 206 also processes the data received by the galvanometer 204 as explained above.

The inhaler 100, 200 may further comprise an acceleration sensor 205. The acceleration sensor 205 is configured to measure the movements of the user during use of the inhaler. The user's galvanic skin reflex may be elevated due to intense physical movement, such as during exercise or brisk walking. In such cases, the galvanometer 204 may detect a high level of stress in the user, although this will not necessarily be in response to emotional stress. In order to minimize such distortions in the determination of stress caused by heavy movements, it is preferable for the user to be in

- 3 042014 at rest. Therefore, measurements made by the galvanometer 204 during any vigorous movements may be ignored by the control device 206 . However, such motion data may be recorded for other purposes such as heart rate detection or general user information.

The inhaler 100, 200 may also include a puff detector 207. In one example, puff detector 207 is connected to a pressure sensor (not shown) that detects air pressure caused by the user's inhaling action. The puff detector 207 detects a puff condition based on a sensor detection result (eg, negative pressure in the inhaler 100, 200). Accordingly, the puff detector 207 can determine the number of times the puff action is performed when the aerosol is inhaled. The puff detector 207 may also detect the period of time required for one puff action while inhaling the aerosol.

The inhaler 100, 200 may also include a memory 208, a light emitting element 209, and other modules 210 such as a display and a sound emitter. A light emitting element 209, such as an LED, may be located at the extreme point of the end 102 without a mouthpiece. Such an LED may exhibit a first light emitting mode in a puff state when an aerosol is inhaled and a second light emitting mode different from the first light emitting mode in a non-puff state when no aerosol is inhaled. Here, the light emitting mode is determined by a combination of parameters such as the amount of light of the light emitting element, the number of light emitting elements in the luminous state, the color of the light emitting element, and the cycle in which the illumination of the light emitting element and the absence of illumination of the light emitting element are repeated. A different light emitting mode means that at least one of any of the above parameters is different.

In FIG. 3A shows a block diagram 300A of the operation of the inhaler 100, 200. In step 301, the aerosol generating device is activated. In the present example, the aerosol source 201 may be heated or vaporized to release the aerosol when the user presses the activation switch 104 on the inhaler 100. A predetermined operation of the switch 104, such as continuously pressing a predetermined number of times, turns on the power source 203 of the inhaler 100, 200. When the operation of the switch 104 turns on power supply 203, power supply 203 supplies power to vaporizer 202, galvanometer 204, controller 206, and other components in inhaler 100, 200.

At 302, a baseline GSR or user stress range is determined. In the present example, the control device 206 calculates the user's baseline GSR based on the readings obtained from the galvanometer 204 over time, ie through a continuous learning process. The baseline galvanic skin reflex can be used as an indication of the user's optimal stress level. Because a user's stress level may vary throughout the day depending on a number of factors, it is preferable to define a baseline GSR range with an upper GSR limit and a lower GSR limit. The baseline range includes all GSR values within the high value and the low value within the given period. This provides the ability to track stress levels with more flexibility. In addition, each user has a different normal skin conductivity, and it may not be possible to set a fixed value as a baseline. The baseline range for a user may change over time as more user data becomes available. It should be understood that the base level range can be stored in the device memory 208 and easily retrieved by the control device 206 at step 302.

There is also an upper safety margin, which is typically higher than the upper GSR bound. GSR measurements that are above the upper safety limit are believed to indicate abnormal levels of stress that are potentially harmful or may become harmful. An upper security limit or threshold can be set for all users. Alternatively, an upper safety limit may be calculated based on user-specific factors such as age, weight, and gender.

At step 303, the galvanic skin reflex of the user is measured. In the present example, the galvanometer 204 activates the user's galvanic skin reflex electrodes when the user presses the activation switch 104 in the inhaler 100 and/or holds the inhaler 200 sideways. As previously described, the user's stress level is determined based on the galvanic skin reflex. In the present example, galvanometer 204 sends measured galvanic skin reflex readings to controller 206 to determine the user's stress level. Preferably, the control device 206 may average the plurality of received readings and determine the user's stress level based on the algorithm and the user's recorded historical data.

At 304, it is determined if the measured GSR is within the range of the baseline. In the present example, the controller 206 determines whether the measured GSR obtained in step 303 is included in the baseline GSR range determined or extracted in step 302. When compared, the controller 206 determines whether the GSR is outside the upper or lower bounds.

- 4 042014 basic level. If not, then controller 206 proceeds to block 305, or otherwise proceeds to block 306. In the present example, if the measured GSR is not within the range of the base level, the measured GSR must either be above the upper limit of the base level or below the lower limit. baseline boundaries.

At step 305, the amount of substance in the aerosol is maintained at the same level. In the present example, when the measured GSR is within the baseline range, the controller 206 may conclude that the user's stress level is within the optimal range and therefore continue to deliver the aerosol from the source 201 unchanged. As a result, the user continues to inhale the same amount of substance (eg nicotine).

At step 320, it is determined if the measured GSR is above the upper safety limit. As mentioned, GSR levels that are above the upper safety limit are considered anomalous. In the present example, upon determining that the measured GSR is above the upper safety limit, the controller 206 performs a safety action at step 321. The safety action may include reducing the amount of the agent in the aerosol or suspending the operation of the inhaler 100, 200. Additionally or alternatively, the safety action The security of the control device 206 may include generating a visible alert using the light emitting element 209 or playing an audible alert. These alerts can be interpreted by the user as warning messages, whereby the user can take retaliatory action to reduce their stress level so as to fall back below the upper safety limit.

At step 306, it is determined if the measured GSR is above the upper bound of the baseline. In the present example, after determining that the measured GSR is outside the baseline range but still below the upper safety limit, the control device 206 further determines if the measured GSR is outside the baseline upper limit, which is a threshold for elevated GSR. When the user's GSR is higher than the upper baseline, this may indicate that the user is in an above-normal state of stress, albeit within safe levels (i.e., below the upper safety limit), and hence the controller 206 proceeds to step 308. On the other hand, when the measured GSR does not exceed the base level upper limit, the controller 206 concludes that the measured GSR value is below the base level lower limit, since the base level out of range result at step 304 provides only two options: either being above the upper limit of the base level, or below the lower limit of the base level. In this case, the controller 206 proceeds to step 307.

At step 307, the control device 206 is configured to control the amount of substance in the aerosol based on user preferences or other data.

In the present example, when the measured GSR is outside the baseline range but not above the baseline upper limit, the controller 206 concludes that the measured GSR is less than the baseline lower limit, indicating very low stress levels. When nicotine is used as the substance, it is well known that a certain amount of nicotine is beneficial in reducing stress and calming the user. On the other hand, increased amounts of nicotine may also provide mental alertness and promote concentration. While a lower GSR value may indicate that the user is at rest, it may also indicate that the user is feeling sleepy and having difficulty doing work. In one scenario, control device 206 may control the amount of substance in the aerosol to maintain a physiologically relaxed state and low stress levels. This can be achieved by maintaining the amount of the agent in the aerosol or by reducing the amount of the agent, depending on the preference of the user. In one example, control device 206 may store or reduce the amount of substance based on the time of day, such as after 8 pm. For example, the user may prefer to maintain a physiologically relaxed state so as to have uninterrupted sleep. The control device 206 may also maintain or reduce the amount of substance in the aerosol based on other data, such as the frequency of vaping. It has been found that the frequency of vaping or duration of vaping puffs can be an indication of the user's relaxed state, and lower vaping frequency can indicate that the user is willing to maintain a relaxed state. Therefore, the control device may maintain or reduce the amount of substance in the aerosol at 307 if the hovering frequency or hovering puff duration is below a predetermined threshold. In another scenario, at step 307, the controller 206 may increase the amount of substance in the aerosol. This can be done to increase the GSR value so that it is again within the range of the baseline. This may be particularly desirable during work hours, when the user may wish to maintain normal stress levels. In this scenario, at step 307, the controller 206 may increase the amount of substance in the aerosol to provide stimulation and make the user more active and alert. This can be done in several ways

- 5 042014 soami. In one example, the amount of aerosol released from source 201 can be increased, thereby increasing the amount of substance to be inhaled by the user. In another example, a multi-tank vaping device may be used, comprising two or more liquid reservoirs, each containing a liquid with a different concentration of a substance. By switching the supply to a reservoir containing a liquid of higher concentration, the amount of consumed substance can be increased while maintaining the same amount of aerosol. In yet another example, substance delivery can be increased by controlling the heating operation (e.g., by controlling the energy supplied to the heater) in non-combustion and vapor-based devices, or by controlling a pressurized liquid source in vapor-based devices. The control device 206 may increase the amount of substance in the aerosol based on the user's preferences or based on other data such as time of day or vaping frequency. In particular, the controller 206 may, at step 307, increase the amount of the agent in the aerosol if the time of day coincides with the user's normal work schedule. This can be set to 9am to 5pm, Monday to Friday, but it can also be adjusted based on user preference or other data that indicates a different work schedule. The controller 206 may also at 307 obtain data relating to the vaporization frequency or duration of the vaporization puffs, and may increase the amount of substance in the aerosol when the vaporization frequency is above a predetermined threshold. Users vaping have been found to take more frequent puffs or longer puffs when they wish to maintain a normal state of attention, and this can be detected by control device 206 to achieve the desired state of attention based on GSR measurements.

At step 308, the amount of substance in the aerosol is increased. In the present example, if the user's GSR is above the upper baseline, this may indicate that the user is agitated or under severe stress. Some nicotine may be helpful in reducing stress and calming the user, and it has also been noted that cigarette smokers tend to smoke more when stressed. Thus, upon determining that the user's GSR is above the upper baseline but still within the safe range (ie, below the safety limit), the controller 206 will increase the amount of the agent in the aerosol to comfort the user.

In FIG. 3B shows a block diagram 300B of additional optional steps in the method of FIG. 3A. It should be understood that the steps in flowchart 300B, while preferred, are not essential to the operation of the present invention.

Continuing after step 304, the controller 206 determines if the measured GSR is within the range of the baseline, as described above. If it is determined that the measured GSR is within the baseline range, the controller 206 proceeds to step 309, otherwise it proceeds to step 310.

At 309, it is determined if longer or more frequent puffs are detected. In the present example, the puff detector 207 detects each time the user takes a puff of the aerosol through the inhaler 100. The puff detector 207 continuously monitors the frequency and duration of puffs taken by the user and reports these puffs to the controller 206. Controller 206 preferably compares puff frequency and duration with historical user puff data that may be stored in memory 208. If controller 206 determines that puffs are becoming more frequent and/or longer than normal, it proceeds to step 311, otherwise it proceeds to step 312.

At step 311, the amount of substance in the aerosol is increased. In the present example, upon determining that the puffs have become more frequent and/or longer, the controller 206 may conclude that the user desires to increase the amount of substance consumed, and therefore it increases the amount of substance in the aerosol delivered to the user. Thus, the user's preference is satisfied without the need for any user intervention. Moreover, by continuously monitoring the user's vaping pattern, a baseline of puff frequency and duration can be determined. Deviations from the baseline can also help determine emotional state. For example, longer and more frequent puffs may indicate more stress.

At step 312, the amount of substance in the aerosol is maintained at the same level. In the present example, if the controller 206 determines that the frequency and duration of puffs is normal, as interpreted from historical puff data, the controller 206 takes no further action and continues to deliver the aerosol with the same amount of substance as before. .

Referring again to step 304, if the measured GSR is found to be outside the baseline range, then at step 310 it is determined whether heavy user movements have been detected. In the present example, the acceleration sensor 205 detects any heavy movements of the user while vaping, such as brisk walking. It is known that such movements can increase

- 6 042014 read the user's GSR, but do not necessarily indicate the level of stress. The acceleration sensor 205 preferably transmits such movements to the control device 206 . The controller proceeds to step 313 if such data is received by the acceleration sensor 205, otherwise proceeds to step 320.

At step 313, the measured GSR is ignored. In the present example, after detecting the user's movements, the controller 206 concludes that the measured GSR is outside the baseline range due to such movements. Therefore, the controller 206 ignores the measured GSR over this period, since it is unlikely to be indicative of the user's actual stress level. In this way, any error caused by the user's movements is avoided. The controller 206 then proceeds to step 309 to check the puff data as explained above.

In FIG. 4 shows a graph 400 of a user's stress level during a typical week. With days of the week plotted on the x-axes and stress levels plotted on the y-axes, a user stress model can be built. In the present example, the user stress model resembles a sinusoidal signal of various amplitudes. The non-resonant line superimposed on the stress model represents the default baseline stress level that is not optimized for a particular user in a given time period. However, for any given day, a user's stress level may vary throughout the day, starting with a low stress level in the morning, peaking during the day, and declining again at night. During the week, stress levels can vary from day to day. Typically, stress levels can be higher on weekdays and lower on weekends. In the example shown, Wednesday is the most stressful day, eg due to high workload, and Saturday is the least stressful day, eg due to free time at home.

It should be understood that graph 400 shows only one possible example of a user stress model considering a typical week. Another user with a different lifestyle may have a completely different model. For example, a user who works weekends or night shifts may have high levels of stress during weekends and at night. Also, the stress pattern may be different when the user is not at work, such as on vacation or during social events. Therefore, the control device 206 continuously monitors the user's stress pattern over different periods of time and continues to learn to update the baseline range. It should also be understood that graph 400 is intended to illustrate the change in stress over time, and the baseline range has been simplified to a curve for simplicity without displaying an upper bound and a lower bound.

In FIG. 5 shows a graph 500 of user GSR data over different time periods. In graph 500, the x-axis represents the time periods in which the stress level is measured, and the y-axis represents the values of GSR or skin electrical conductivity in microsiemens (µS). The galvanometer 204 measures the galvanic skin reflex of the user, and the controller 206 records it every time period.

As explained above, the controller 206 also defines a user's baseline range with upper and lower baseline limits. The controller 206 also defines an upper security bound, which is either user-specific or default. As shown, in the first period, the user's GSR is determined to be 3 µS, which is within the range between the upper baseline limit having a value of 4 and the baseline lower limit having a value of 2. However, in the second period, the measured GSR is 12 μS, which is higher than the upper baseline limit of 10. As explained above, when the controller 206 determines that the measured GSR is outside the baseline, it adjusts the amount of the agent in the aerosol. The control device 206 thus ensures that the user's stress level remains at an optimal level for a given time of day or according to the user's preference. In this example, the measured GSR is below the upper safety limit all the time.

Using the invention described above, the user's stress level can be monitored without the use of any additional device or the need for the user to perform any additional step. In addition, by controlling the delivery of the aerosol based on the determined stress level, it is possible to keep the user's stress level at a baseline or optimal level most of the time. This allows the user to vape without having to consciously monitor aerosol consumption.

In the invention described above, stress readings may be presented to the user via a small display on the inhaler. Additionally, it is possible to notify the user of a high or low level of stress by flashing a multi-colored LED or by playing an audible alert. Additionally or alternatively, the inhaler can be connected to the user's personal device, such as a mobile phone or smartphone, which can run an application (e.g., iOS/Android App) to display to the user of the inhaler the current stress level, movement data, puff data, amount of aerosol consumed, and etc. V

-

Claims (13)

user-friendly format. Such a device, when connected to an inhaler, may also be configured to receive various measurements from the inhaler and determine a baseline, as described above. The previous description of illustrative embodiments has been presented for purposes of illustration and description. It is not intended to be exhaustive or limiting as to the precise form disclosed, and modifications and changes are possible in light of the teachings above or by practice of the disclosed embodiments. CLAIM 1. A vaping device generating an aerosol, comprising: a housing having an air flow path defined between an air inlet and an air outlet of the housing, the air outlet providing an outlet for the generated aerosol; a galvanometer located on the body of the vaping device, wherein the galvanometer is configured to measure the galvanic skin reflex to determine the stress level of the user of the vaping device; and a control device configured to control the release of the aerosol based on a determined level of stress, the control device further configured to determine the user's baseline galvanic skin reflex level using measurements taken by the galvanometer at different time translations. 2. The aerosol generating vaping device according to claim 1, characterized in that the galvanometer is built into the vaping device activation switch such that the user's skin comes into contact with the galvanometer when the user interacts with the activation switch to activate the vaping device. 3. An aerosol generating vaping device according to claim 1 or 2, characterized in that the galvanometer is located on the side surface of the vaping device such that the user's skin comes into contact with the galvanometer when the user holds the vaping device during use. 4. An aerosol generating vaping device according to any one of the preceding claims, characterized in that the vaping device further comprises an acceleration sensor for detecting the movements of the user during use of the vaping device. 5. An aerosol generating vaping device according to claim 4, characterized in that the control device is configured to ignore the galvanic skin reflex measured by the galvanometer based on movements detected by the acceleration sensor. 6. An aerosol generating vaping device according to any one of the preceding claims, characterized in that the base level galvanic skin reflex provides a range with a base level upper limit and a base level lower limit. 7. An aerosol generating vaping device according to claim 6, characterized in that the control device is configured to increase or decrease the amount of substance in the aerosol when the measured galvanic skin reflex is outside the baseline galvanic skin reflex. 8. An aerosol generating vaping device according to any one of the preceding claims, characterized in that the control device is configured to determine the number of puffs inhaled by the user per unit of time, or the average puff duration. 9. A method of operating a vaping device that generates an aerosol, including activating the vaping device to release aerosol from the vaping device; measurement of the galvanic skin reflex with determination of the stress level of the user using a galvanometer located on the main part of the vaping device; and controlling the release of the aerosol based on the determined stress level, wherein a baseline galvanic skin reflex is determined from the user using measurements taken by the galvanometer at different times. 10. The method of claim 9, further comprising detecting the user's movements when using the vaping device. 11. The method of claim 10, further comprising ignoring the galvanic skin reflex measured by the galvanometer based on detected movements. 12. Method according to any one of claims 9 to 11, characterized in that the base level galvanic skin reflex provides a range with an upper base level limit and a lower base level limit. 13. The method according to any one of claims 9 to 12, further comprising increasing or decreasing the amount of substance in the aerosol when the measured galvanic skin reflex is outside the baseline galvanic skin reflex. -